German court foils Novartis' gliptin AMNOG bid
This article was originally published in Scrip
Executive Summary
Novartis' attempt to block Germany from retrospectively assessing its gliptin Galvus crashed on 15 May as a German court promptly dismissed the suit, snuffing out hope for an escape from price cuts for all companies with marketed drugs in that class.